These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8772595)

  • 1. The effect of hypopituitarism on life expectancy.
    Bates AS; Van't Hoff W; Jones PJ; Clayton RN
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1169-72. PubMed ID: 8772595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and late prognosis of cushing's syndrome: a population-based study.
    Lindholm J; Juul S; Jørgensen JO; Astrup J; Bjerre P; Feldt-Rasmussen U; Hagen C; Jørgensen J; Kosteljanetz M; Kristensen L; Laurberg P; Schmidt K; Weeke J
    J Clin Endocrinol Metab; 2001 Jan; 86(1):117-23. PubMed ID: 11231987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Life expectancy following surgery for pituitary tumours.
    Bates AS; Bullivant B; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1999 Mar; 50(3):315-9. PubMed ID: 10435056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients.
    Fernandez-Rodriguez E; Lopez-Raton M; Andujar P; Martinez-Silva IM; Cadarso-Suarez C; Casanueva FF; Bernabeu I
    Clin Endocrinol (Oxf); 2013 Feb; 78(2):278-84. PubMed ID: 22845165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality.
    Burman P; Mattsson AF; Johannsson G; Höybye C; Holmer H; Dahlqvist P; Berinder K; Engström BE; Ekman B; Erfurth EM; Svensson J; Wahlberg J; Karlsson FA
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1466-75. PubMed ID: 23457412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.
    Tomlinson JW; Holden N; Hills RK; Wheatley K; Clayton RN; Bates AS; Sheppard MC; Stewart PM
    Lancet; 2001 Feb; 357(9254):425-31. PubMed ID: 11273062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the morphological evaluation of the pituitary and the growth hormone (GH) response to GH-releasing hormone Plus arginine in children and adults with congenital hypopituitarism.
    Maghnie M; Salati B; Bianchi S; Rallo M; Tinelli C; Autelli M; Aimaretti G; Ghigo E
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1574-9. PubMed ID: 11297586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis.
    Mukherjee A; Murray RD; Columb B; Gleeson HK; Shalet SM
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):743-8. PubMed ID: 14974916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
    Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypopituitarism and mortality in pituitary adenoma.
    Lindholm J; Nielsen EH; Bjerre P; Christiansen JS; Hagen C; Juul S; Jørgensen J; Kruse A; Laurberg P; Stochholm K
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):51-8. PubMed ID: 16817819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premature mortality due to cardiovascular disease in hypopituitarism.
    Rosén T; Bengtsson BA
    Lancet; 1990 Aug; 336(8710):285-8. PubMed ID: 1973979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and predictive factors of post-traumatic hypopituitarism.
    Klose M; Juul A; Poulsgaard L; Kosteljanetz M; Brennum J; Feldt-Rasmussen U
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):193-201. PubMed ID: 17524035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is vascular mortality increased in hypopituitarism?
    Erfurth EM; Bülow B; Hagmar LE
    Pituitary; 2000 Oct; 3(2):77-81. PubMed ID: 11141699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality, cardiovascular events and risk factors in hypopituitarism.
    Clayton RN
    Growth Horm IGF Res; 1998 Feb; 8 Suppl A():69-76. PubMed ID: 10993595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort.
    Lhatoo SD; Johnson AL; Goodridge DM; MacDonald BK; Sander JW; Shorvon SD
    Ann Neurol; 2001 Mar; 49(3):336-44. PubMed ID: 11261508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan's syndrome).
    Zargar AH; Singh B; Laway BA; Masoodi SR; Wani AI; Bashir MI
    Fertil Steril; 2005 Aug; 84(2):523-8. PubMed ID: 16084902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency.
    Elhadd TA; Abdu TA; Oxtoby J; Kennedy G; McLaren M; Neary R; Belch JJ; Clayton RN
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4223-32. PubMed ID: 11549653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the skin characteristics in patients with severe GH deficiency and the effects of 6 months of GH replacement therapy: a randomized placebo controlled study.
    Tanriverdi F; Borlu M; Atmaca H; Koc CA; Unluhizarci K; Utas S; Kelestimur F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):579-85. PubMed ID: 17054457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.